Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 5, 2025
Deals
Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz
Building in oncology, Jazz obtains targeted glioma therapy under FDA review
BioCentury | Dec 21, 2022
Deals
Jazz in tune with Zymeworks’ biliary cancer data, opts in for $325M
Deepening commitment to oncology, Jazz elects to maintain license for dual HER2 bispecific; Phase IIb results this week could suffice for targeted approval
BioCentury | Oct 26, 2022
Finance
Oct. 26 Quick Takes: Vaxcyte prices year’s second-largest follow-on
Plus AZ’s AKT inhibitor hits co-primary endpoints in breast cancer trial, and updates from Time BioVentures, Seres, Jazz and GSK
BioCentury | Oct 19, 2022
Deals
With biliary readout looming, Jazz-Zymeworks deal could grow much larger
Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout
BioCentury | Apr 8, 2022
Deals
Werewolf deal gives Jazz first immuno-oncology candidate
Jazz pays $15M up front to in-license rights to Werewolf’s conditionally activated oncology therapeutic
BioCentury | Feb 4, 2021
Deals
Jazz strikes another chord in neuroscience via $7.2B GW pickup
With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather
BioCentury | Dec 3, 2020
Product Development
After Phase III miss, PharmaMar and Jazz may need new monotherapy trial to confirm cancer drug’s benefit
PharmaMar will likely need to conduct a new study of Zepzelca to gain its full approval after the drug failed to show a survival benefit in a potentially confirmatory Phase III trial to treat small
BioCentury | Jun 17, 2020
Product Development
June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more
BioCentury | Feb 18, 2020
Regulation
Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more
BioCentury | Dec 19, 2019
Company News
PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline
Items per page:
1 - 10 of 35